Sulfas neomycin, hydrocortisone acetate - otsingu tulemused

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

sulfasalazine tablet

remedyrepack inc. - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and b) for the prolongation of the remission period between acute attacks of ulcerative colitis. sulfasalazine tablets are contraindicated in: patients with intestinal or urinary obstruction, patients with porphyria as sulfonamides have been reported to precipitate an acute attack, patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates. none reported.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

sulfasalazine delayed-release tablet

qualitest pharmaceuticals - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg

Malta - inglise - Medicines Authority

sulfasalazin-heyl

heyl chem.-pharm. fabrik gmbh & co. kg goerzallee 253, d-14167 berlin, germany - sulfasalazine - gastro-resistant tablet - sulfasalazine 500 mg - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

naglazyme- galsulfase solution

biomarin pharmaceutical inc. - galsulfase (unii: 59ua429e5g) (galsulfase - unii:59ua429e5g) - galsulfase 5 mg in 5 ml - naglazyme is indicated for patients with mucopolysaccharidosis vi (mps vi, maroteaux-lamy syndrome). naglazyme has been shown to improve walking and stair-climbing capacity. none. risk summary available data from case reports and postmarketing experience with naglazyme use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, galsulfase administered intravenously to pregnant rats and rabbits during the period of organogenesis, showed no evidence of harm to the fetus at doses of about 0.5 and 0.97 times, respectively for rats and rabbits, the recommended human dose of 1 mg/kg based on body surface area (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of majo